Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More
AUROBINDO PHARMA | ORCHID PHARMA | AUROBINDO PHARMA/ ORCHID PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 17.8 | -18.5 | - | View Chart |
P/BV | x | 3.9 | 5.3 | 72.9% | View Chart |
Dividend Yield | % | 0.3 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
ORCHID PHARMA Sep-13 |
AUROBINDO PHARMA/ ORCHID PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 194 | 427.8% | |
Low | Rs | 527 | 35 | 1,506.0% | |
Sales per share (Unadj.) | Rs | 333.9 | 276.5 | 120.8% | |
Earnings per share (Unadj.) | Rs | 40.4 | -79.2 | -50.9% | |
Cash flow per share (Unadj.) | Rs | 51.8 | -43.5 | -119.1% | |
Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
Dividend yield (eoy) | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 237.1 | 53.9 | 439.5% | |
Shares outstanding (eoy) | m | 585.91 | 70.45 | 831.7% | |
Bonus/Rights/Conversions | ESOP | ESOP | - | ||
Price / Sales ratio | x | 2.0 | 0.4 | 490.7% | |
Avg P/E ratio | x | 16.8 | -1.4 | -1,163.2% | |
P/CF ratio (eoy) | x | 13.1 | -2.6 | -497.5% | |
Price / Book Value ratio | x | 2.9 | 2.1 | 134.8% | |
Dividend payout | % | 6.2 | 0 | - | |
Avg Mkt Cap | Rs m | 397,569 | 8,067 | 4,928.6% | |
No. of employees | `000 | 17.9 | 2.8 | 637.7% | |
Total wages/salary | Rs m | 25,849 | 2,527 | 1,022.9% | |
Avg. sales/employee | Rs Th | 10,956.9 | 6,956.1 | 157.5% | |
Avg. wages/employee | Rs Th | 1,447.7 | 902.5 | 160.4% | |
Avg. net profit/employee | Rs Th | 1,324.3 | -1,993.0 | -66.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 19,477 | 1,004.4% | |
Other income | Rs m | 1,553 | 407 | 381.4% | |
Total revenues | Rs m | 197,189 | 19,884 | 991.7% | |
Gross profit | Rs m | 39,519 | 1,103 | 3,584.2% | |
Depreciation | Rs m | 6,680 | 2,519 | 265.1% | |
Interest | Rs m | 2,626 | 5,227 | 50.2% | |
Profit before tax | Rs m | 31,767 | -6,236 | -509.4% | |
Minority Interest | Rs m | 27 | 20 | 137.1% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 511 | -172.3% | |
Tax | Rs m | 7,269 | -125 | -5,805.5% | |
Profit after tax | Rs m | 23,645 | -5,580 | -423.7% | |
Gross profit margin | % | 20.2 | 5.7 | 356.8% | |
Effective tax rate | % | 22.9 | 2.0 | 1,139.7% | |
Net profit margin | % | 12.1 | -28.7 | -42.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 11,014 | 1,395.0% | |
Current liabilities | Rs m | 120,429 | 32,060 | 375.6% | |
Net working cap to sales | % | 17.0 | -108.1 | -15.7% | |
Current ratio | x | 1.3 | 0.3 | 371.4% | |
Inventory Days | Days | 135 | 95 | 142.5% | |
Debtors Days | Days | 64 | 34 | 189.8% | |
Net fixed assets | Rs m | 103,909 | 29,440 | 353.0% | |
Share capital | Rs m | 586 | 705 | 83.2% | |
"Free" reserves | Rs m | 138,322 | 2,043 | 6,771.9% | |
Net worth | Rs m | 138,908 | 3,800 | 3,655.6% | |
Long term debt | Rs m | 1,800 | 9,018 | 20.0% | |
Total assets | Rs m | 264,544 | 46,510 | 568.8% | |
Interest coverage | x | 13.1 | -0.2 | -6,781.9% | |
Debt to equity ratio | x | 0 | 2.4 | 0.5% | |
Sales to assets ratio | x | 0.7 | 0.4 | 176.6% | |
Return on assets | % | 9.9 | -0.8 | -1,306.6% | |
Return on equity | % | 17.0 | -146.9 | -11.6% | |
Return on capital | % | 23.8 | -3.7 | -638.2% | |
Exports to sales | % | 49.6 | 37.9 | 131.0% | |
Imports to sales | % | 18.8 | 22.6 | 83.0% | |
Exports (fob) | Rs m | 97,091 | 7,378 | 1,316.0% | |
Imports (cif) | Rs m | 36,741 | 4,406 | 833.9% | |
Fx inflow | Rs m | 97,316 | 7,513 | 1,295.3% | |
Fx outflow | Rs m | 40,589 | 5,649 | 718.5% | |
Net fx | Rs m | 56,727 | 1,865 | 3,042.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 1,682 | 964.5% | |
From Investments | Rs m | -28,768 | -9,860 | 291.8% | |
From Financial Activity | Rs m | 19,191 | 6,644 | 288.8% | |
Net Cashflow | Rs m | 6,656 | -1,535 | -433.6% |
Indian Promoters | % | 54.1 | 32.3 | 167.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 4.6 | 172.8% | |
FIIs | % | 27.7 | 3.3 | 839.4% | |
ADR/GDR | % | 0.0 | 4.6 | - | |
Free float | % | 10.2 | 55.3 | 18.4% | |
Shareholders | 69,601 | 84,811 | 82.1% | ||
Pledged promoter(s) holding | % | 8.6 | 54.9 | 15.6% |
Compare AUROBINDO PHARMA With: FRESENIUS KABI ONCO. DIVIS LABORATORIES FULFORD INDIA ALKEM LABORATORIES ELDER PHARMA
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More